Immunotherapy

Papers
(The median citation count of Immunotherapy is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study82
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So €˜Pure’67
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study57
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia46
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study36
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar32
Imaging of brain metastases treated with immune checkpoint inhibitors32
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma28
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma27
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma27
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression25
Immunotherapy for Gastric Cancer: A 2021 Update21
Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey21
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas17
Postvaccination immune-mediated hepatitis: what do we really know?17
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-15816
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review16
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?16
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data15
Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy14
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis14
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors14
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?13
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors13
Cancer Immunotherapy Via Stem Cell-Derived NK Cells13
Safety and Efficacy of Mutant Neoantigen-Specific T-Cell Treatment Combined Anti-Pd-1 Therapy in Stage Iv Solid Tumors13
Assessing Pd-L1 Status in Mrcc Treated with First-Line Immune-Based Combinations: A Meta-Analysis13
Durvalumab after Chemoradiotherapy in Patients with Stage III Non-Small-Cell Lung Cancer: Real-World Outcomes Versus Clinical Trial Results13
Uveitis Associated with Cancer Immunotherapy: Long-Term Outcomes13
Anlotinib Succeeded in Rescue Therapy For Hyperprogression Induced by Immune Checkpoint Inhibitors: A Case Report13
Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer13
Nivolumab induced discolouration of the tongue: a case report13
Adherence, persistence and treatment switching in psoriasis12
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review12
4-1BB Antibody Enhances Cytotoxic Activity of Natural Killer Cells Against Prostate Cancer Cells Via NKG2D Agonist Combined with IL-2712
Efficacy of mIte Allergen Immunotherapy in Allergic Rhinitis and the Immune Synergistic Effect on Cross-Allergens12
Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review12
Liquid biopsy for guiding breast cancer immunotherapy11
Emerging Advances in Nanomedicine for Breast Cancer Immunotherapy: Opportunities and Challenges11
Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins11
SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma11
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management11
Lessons From the Diagnosis and Treatment of Severe Immune Checkpoint Inhibitor-Associated Pneumonia: A Case Report11
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?11
Immune-Checkpoint Inhibitors in Renal Transplanted Patients Affected by Melanoma: A Systematic Review11
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma10
Germinal center immune dynamics: challenges for effective vaccination in the elderly10
Integrase inhibitors: current protagonists in antiretroviral therapy10
Applications and Current Challenges of Chimeric Antigen Receptor T Cells in Treating High-Grade Gliomas in Adult and Pediatric Populations10
Current Immunosuppression Strategies in Pediatric Heart Transplant10
Immune Checkpoint Inhibitors in Cholangiocarcinoma10
Poor Response to Sintilimab Plus Chemotherapy in a Pulmonary Epithelioid Hemangioendothelioma Patient: A Case Report10
Deucravacitinib in Moderate-To-Severe Psoriasis10
Infection Rates and Tolerability of Three Different Immunoglobulin Administration Modalities in Patients with Primary Immunodeficiency Diseases10
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics10
Effectiveness of COVID-19 Vaccines Against Omicron Variant9
Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature9
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens9
A Summertime Pause in Immunoglobulin Replacement Therapy: A Prospective Real-World Analysis9
Immune-Related Gigantomastia: A Case Study9
Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary9
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer9
Human Growth Hormone Supplement Promotes Human Lymphohematopoietic Cell Reconstitution in Immunodeficient Mice9
Steroid-Dependent Polyarthritis Induced by Immune Checkpoint Inhibitor Therapy Successfully Treated with Bimekizumab8
Impact of Helicobacter Pylori Infection on The Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis8
Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis8
Late-Onset Toxicities of Monoclonal Antibodies in Cancer Patients8
Therapeutic Intervention of Glioma with the Novel Antineoplastic Agent T11TS: The Story so Far8
TOPAZ-1: A New Standard of Care for Advanced Biliary Tract Cancers?8
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma8
Abrocitinib for the Treatment of Atopic Dermatitis8
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report8
A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer8
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib8
Immune Checkpoint Inhibitors in Lung Tumors with Rare Histologies and Other Thoracic Malignancies8
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs8
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy7
Immunotherapies for prevention and treatment of type 1 diabetes7
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma7
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study7
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China7
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease7
Indirect Comparison of Pembrolizumab Monotherapy Versus Nivolumab + Ipilimumab in First-Line Metastatic Lung Cancer7
Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy7
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes7
Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival7
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database7
Ipilimumab and Nivolumab: The ‘New Kid on the Block’ in Advanced Angiosarcoma7
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)7
Pembrolizumab in an HIV-infected patient with glioblastoma7
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors7
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events7
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab7
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis7
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis7
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study6
The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus6
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis6
Could senescent cells be the prescription for therapeutic cancer vaccines?6
Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary6
Treatment of EAE Mice with Treg, G-MDSC and IL-2: a New Insight into Cell Therapy for Multiple Sclerosis6
Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature6
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases6
Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease6
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?6
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy6
Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review6
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer6
Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy6
An Unusual Case of Immune-Related Gastritis in One Patient Receiving Toripalimab Therapy6
The Effect of Low-Dose Chemotherapy on the Tumor Microenvironment and its Antitumor Activity Combined with Anti-PD-1 Antibody6
Cutaneous Metastases at the Sites of Pembrolizumab-Induced Bullous Pemphigoid Lesions in a Patient with Melanoma6
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis6
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review6
Allogeneic CAR-T cells for cancer immunotherapy6
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas6
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis6
Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates6
Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?6
The potential of phytomedicines to optimize CAR-T cell therapy in cancer5
ICAM2 is Related to Good Prognosis in Dendritic Cell Immunotherapy for Cancer5
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy5
Anaphylaxis to Tocilizumab in Patients with Rheumatic Disease5
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis5
Neoadjuvant Immunochemotherapy in the Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: A Systematic Review5
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study5
Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study5
Efficacy of Long-Term Repeated Rituximab Treatment in Refractory Phospholipase A2 Receptor-Antibody-Related Membranous Nephropathy5
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors5
Radiation and Resolve: Unlocking the Synergistic Potential of Radioimmunotherapy in Advanced Lung Cancer Management5
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review5
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations5
Pd-1/L1 Inhibitors May Increase the Risk of Pericardial Disease in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis and Systematic Review5
Infrequent Liver Injury from Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma5
Targeting the Tumor Microenvironment of Ewing Sarcoma5
Oncolytic Viruses in Lung Cancer Treatment: A Review Article5
Amalgamation of Nanotechnology with Chicken IgY to Enrich Therapeutic and Diagnostic Applications: A Systematic Review5
Cemiplimab-Induced Cytokine-Release Syndrome: Second Case Reported and Review of The Literature5
Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy5
The Use of Dostarlimab, a Safe and Efficient Monotherapy in Msi-H Rectal Cancer Patients, an Alternative to Surgery5
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement5
Peripheral Blood Eosinophil Count is Associated with Response to Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer5
A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents5
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy5
Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan5
Peptide–MHC Complexes: Dressing up to Manipulate T Cells Against Autoimmunity and Cancer5
Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment5
Bimekizumab for The Treatment of Psoriasis5
A CD123-Specific Chimeric Antigen Receptor Augments Anti-Acute Myeloid Leukemia Activity of Vγ9Vδ2 T Cells5
Tsunami of Immunotherapies in the Management of Esophageal Cancer5
Immunotherapy in Atopic Dermatitis4
Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report4
Mirna Profiles Change During Grass Pollen Immunotherapy Irrespective of Clinical Outcome4
Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report4
Thyroid Function Impairment after Chemo-Immunotherapy for Advanced Nsclc: A Single Institutional Retrospective Report4
Successful Use of Secukinumab in Two Melanoma Patients with Immune Checkpoint Inhibitor-Induced Inflammatory Arthropathy4
Drug evaluation: mepolizumab in chronic obstructive pulmonary disease4
Cost–Effectiveness Analysis of Nivolumab Plus Cabozantinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma4
A Review of Phase Iii Clinical Trials of Us Fda-Approved Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyposis4
Evaluating stapokibart in the treatment of seasonal allergic rhinitis4
Safety and Effectiveness of Intravenous Ct-P13 in Inflammatory Arthritis: Post-Marketing Surveillance Study in Thailand4
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event4
Satisfaction, Qol and adherence of patients allergic to dust mites and/or pollens undergoing sublingual immunotherapy4
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice4
Severe Pseudomembranous Keratoconjunctivitis with Deterioration of Eyesight Induced by Immune Checkpoint Inhibitors4
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease4
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives4
Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial4
Effect of Neoadjuvant Therapy on Tumor Tissue PD-L1 and VISTA Expression Levels in Non-Small-Cell Lung Cancer4
Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events4
Pembrolizumab-Induced Follicular Eruption and Response to Isotretinoin4
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy4
Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults4
Metastatic Gastric Cancer: Synergizing and Sequencing Targeted Therapy with First-Line Immunotherapy4
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?4
Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack4
Overcoming Immune-Resistance in Laryngeal Cancer: A Case Report of the Abscopal Effect and Nivolumab Beyond Progression4
Systemic Immune–Inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis4
Imaging-calculated splenic volume is associated with response in melanoma patients treated with immunotherapy4
Multicenter Real-World Experience with Epinephrine 0.5 mg Dosing for Anaphylaxis with Allergen Immunotherapy4
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis4
Tezepelumab for the Treatment of Severe Asthma: A Plain Language Summary of the PATHWAY and NAVIGATOR Studies4
Immunology of Osteoporosis: Relevance of Inflammatory Targets for the Development of Novel Interventions4
Enhanced Binding at Fever Temperatures of HER2 in Complex with Trastuzumab and Pertuzumab4
Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center4
Immune Checkpoint Inhibitors and Combinations with Other Agents in Cholangiocarcinoma4
Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation4
Targeting CD47 Enhanced the Antitumor Immunity of PD-L1 Blockade in B-Cell Lymphoma3
Immunotherapy for Head and Neck Cancer: Where do We Go from Here?3
Targeted Allergen-Specific Immunotherapy within the Skin Improves Allergen Delivery to Induce Desensitization to Peanut3
Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases3
Immune Checkpoint Inhibitor-Related Chronic Pneumonitis: A Case Report and Literature Review3
Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors3
Surrogate end Points for Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors3
Galectin-9 and PD-L1 Antibody Blockade Combination Therapy Inhibits Tumour Progression in Pancreatic Cancer3
The role of dupilumab in the treatment of eosinophilic esophagitis3
Sintilimab Plus Sorafenib: A novel Regimen for Hepatocellular Carcinoma3
Interpatient Variability in Mesothelin Expression Necessitates its Evaluation Before Gastric Cancer Immunotherapy3
Reversing Chemokine/Chemokine Receptor Mismatch to Enhance the Antitumor Efficacy of CAR-T Cells3
Failure of immune checkpoint inhibitors for microsatellite instability-positive pancreatic adenocarcinoma with atypical pattern of short tandem repeat mutation3
The role of nemolizumab in the treatment of atopic dermatitis for the adult population3
Safety of Subcutaneous and Sublingual Immunotherapy with Allergoids in Children: A Real-Life Pharmacovigilance Study3
Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia3
Immunoregulatory Effects of Dental Mesenchymal Stem Cells on T and B Lymphocyte Responses in Primary Sjögren's Syndrome3
Plain Language Summary of the VOLTAIRE-RA in Patients with Moderate-To-Severe Rheumatoid Arthritis3
Prognostic value of peripheral blood neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, pan-immune-inflammation value and systemic immune-inflammation index for the efficacy of immunotherapy in p3
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?3
Outcomes for Pembrolizumab Stratified by Pemetrexed Maintenance Post Pembrolizumab–Platinum–Pemetrexed Induction in Metastatic Non-Small-Cell Lung Cancer3
Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary3
Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient3
Cost–effectiveness of Adjuvant Atezolizumab for Patients with Stage II–IIIA PD-L1+ Non-Small-Cell Lung Cancer3
Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?3
A Common Approach for Fighting Tuberculosis and Leprosy: Controlling Endoplasmic Reticulum Stress in Myeloid-derived Suppressor Cells3
First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap3
Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy3
The Evolution of Biliary Tract Cancer: Introducing a Special Focus Issue from Immunotherapy3
Evidence for optimal treatment of immune-related adverse events needed – should we use extracorporeal photopheresis?3
Treatment and Prognostic Implications of Strong PD-L1 Expression in Primary Hepatic Sarcomatoid Carcinoma3
Welcome to The 14th Volume of Immunotherapy3
Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics3
Efficacy of Pd-1/Pd-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis3
Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe3
CAR-T cells for H3K27-altered diffuse midline gliomas: where do we stand?3
Complete Response and Survival Outcomes in Patients with Advanced Cancer on Immune Checkpoint Inhibitors3
The role of immune subtyping in glioma mRNA vaccine development3
Combined Application of Bevacizumab and Pd-1 Blockade Displays Durable Treatment Effects by Increasing the Infiltration And Cytotoxic Function of Cd8 + T Cells in Lu3
Efficacy of Therapies Targeting TGF-β in Solid Tumors: a Systematic Review and Meta-Analysis of Clinical Trials3
Etrasimod for the Treatment of Ulcerative Colitis3
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study3
Comparing how Well Abrocitinib and Dupilumab Treat Atopic Dermatitis Signs and Symptoms: A Plain Language Summary3
Autologous Enzyme-Linked Immunosorbent Facilitated Antigen Binding Detects Ige-Blocking Activity Based on Direct Competition between Allergen-specific IgE and Non-IgE3
Alpha/beta-defensins influence on the humoral immunity and complications in cancer of the oral cavity and oropharynx3
Penpulimab and Anlotinib in an Elderly Patient with Recurrent Cervical Cancer: A Case Report and Literature Review3
Immune checkpoint inhibitor-related colitis in a patient with non-small cell lung cancer co-infected with HBV and EBV: a case report3
FHL1 As a Novel Prognostic Biomarker and Correlation with Immune Infiltration Levels in Lung Adenocarcinoma3
Durable Response after Immunotherapy Discontinuation for Delayed and Severe Immune-related Adverse Event: A Case Report3
Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis2
Toripalimab and Fruquintinib Therapy for Colorectal Cancer after Failed Multiline Chemotherapies: A Case Report2
Scalable and cost-effective CAR-T exosome therapies: challenges and future directions2
Evaluating remibrutinib in the treatment of chronic spontaneous urticaria2
Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab2
Pitfalls and strategies of CAR-T therapy in solid tumors and implications for chordoma treatment2
Hematological Prognosticators in Metastatic Renal Cell Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis2
Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data2
Impact of immune-related adverse events on survival among patients with head-and-neck squamous cell carcinoma2
Use of Upadacitinib in the Treatment of Psoriatic Arthritis2
The role of exosomal PD-L1 in NSCLC immunotherapy2
Immunotherapy with γδ T-cells: the future is there2
How could histotripsy change cancer immunotherapy?2
Hyperprogressive Disease in Leiomyosarcoma: A Threat to the Use of Single-Agent Anti-Pd-(L)1 Therapy?2
1.0676169395447